Small Molecules In Oncology (recent Results In Cancer Research)

Extensive research into the molecular mechanisms of cancer disease has heralded a new age of targeted therapy. In malignant cells, key proteins that are crucial to tumor growth and survival are now being targeted directly with rationally designed inhibitors. Apart from monoclonal antibodies, small molecule therapeutics such as oncogenic protein kinase inhibitors are attracting a vast amount of investigational attention. This textbook, written by acknowledged experts, provides a broad overview of the small molecules currently used for the treatment of malignant diseases and discusses interesting novel compounds that are in the process of clinical development to combat cancer. Front Matter....Pages i-xvi Front Matter....Pages 1-1 Imatinib Mesylate....Pages 3-20 Erlotinib....Pages 21-31 Axitinib (AG-013736)....Pages 33-44 Lapatinib....Pages 45-59 Sorafenib....Pages 61-70 Sunitinib....Pages 71-82 Dasatinib....Pages 83-102 Nilotinib....Pages 103-117 Bosutinib....Pages 119-127 Front Matter....Pages 130-130 Decitabine....Pages 131-157 5-Azacytidine/Azacitidine....Pages 159-170 Front Matter....Pages 172-172 Bortezomib....Pages 173-187 Temsirolimus....Pages 189-197 Danusertib (formerly PHA-739358) – A Novel Combined Pan-Aurora Kinases and Third Generation Bcr-Abl Tyrosine Kinase Inhibitor....Pages 199-214 BI_2536 - Targeting the Mitotic Kinase Polo-Like Kinase 1 (Plk1)....Pages 215-218 Front Matter....Pages 220-220 Imetelstat (GRN163L) - Telomerase-Based Cancer Therapy....Pages 221-234 GDC-0449 - Targeting the Hedgehog Signaling Pathway....Pages 235-238 Protein Kinase Inhibitors -- Imatinib Mesylate -- Erlotinib -- Axitinib -- Lapatinib -- Sorafenib -- Sunitinib -- Dasatinib -- Nilotinib -- Bosutinib -- Epigenetic Modifiers -- Decitabine -- 5-azacytidine/azacitidine -- Cell Cycle Inhibitors -- Bortezomib -- Temsirolimus -- Danusertib (formerly Pha-739358): A Novel Combined Pan-aurora Kinases And Third Generation Bcr-abl Tyrosine Kinase Inhibitor -- Bi_2536: Targeting The Mitotic Kinase Polo-like Kinase 1 (plk1) -- Other Novel Agents -- Imetelstat (grn163l): Telomerase-based Cancer Therapy -- Gdc-0449: Targeting The Hedgehog Signaling Pathway. Uwe M. Martens (ed.). Includes Bibliographical References.